Bristol-Myers Squibb & QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-On...
August 30 2015 - 7:00PM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) and QIMR Berghofer
Medical Research Institute have signed a research collaboration and
license agreement to discover novel therapeutic antibodies against
an undisclosed immuno-oncology (I-O) target.
“Bristol-Myers Squibb continues to invest in strategic
partnerships that accelerate the discovery and development of novel
immunotherapies through innovative science and technologies,” said
Carl Decicco, Ph.D., Head of Discovery, R&D, Bristol-Myers
Squibb. “We are excited to work with QIMR Berghofer Medical
Research Institute, a partner that brings significant experience
and expertise in cancer research.”
“QIMR Berghofer is committed to translational research, so it is
gratifying when high quality research at the Institute results in
the strategic collaboration announced today,” said Professor Frank
Gannon, QIMR Berghofer Director and CEO. “Bristol-Myers Squibb is
the ideal partner to progress these assets to the clinic, with
their world-leading expertise in immuno-oncology and a proven track
record developing multiple cancer therapies on the market. We look
forward to a fruitful, long-term collaboration, delivering new
therapies for cancer patients.”
QIMR Berghofer Medical Research Institute is a world leading
translational research institute focused on cancer, infectious
diseases, mental health and a range of complex disorders.
Bristol-Myers Squibb will be solely responsible for clinical
development and commercialization of antibodies discovered through
the collaboration. Financial terms were not disclosed.
Immuno-Oncology at Bristol-Myers Squibb
Surgery, radiation, cytotoxic or targeted therapies have
represented the mainstay of cancer treatment over the last several
decades, but long-term survival and a positive quality of life have
remained elusive for many patients with advanced disease.
To address this unmet medical need, Bristol-Myers Squibb is
leading research in an innovative field of cancer research and
treatment known as Immuno-Oncology, which involves agents whose
primary mechanism is to work directly with the body’s immune system
to fight cancer. The company is exploring a variety of compounds
and immunotherapeutic approaches for patients with different types
of cancer, including researching the potential of combining
Immuno-Oncology agents that target different pathways in the
treatment of cancer.
Bristol-Myers Squibb is committed to advancing the science of
Immuno-Oncology, with the goal of changing survival expectations
and the way patients live with cancer.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit www.bms.com or follow us on Twitter at
http://twitter.com/bmsnews.
About QIMR Berghofer Medical Research Institute
The QIMR Berghofer Medical Research Institute is a world leading
translational research institute focused on cancer, infectious
diseases, mental health and a range of complex disorders. Working
in close collaboration with clinicians and other research
institutes, our aim is to improve health by developing new
diagnostics, better treatments and prevention strategies. For more
information about QIMR Berghofer, visit
www.qimrberghofer.edu.au.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking
statement can be guaranteed. Among other risks, there can be no
guarantee that the collaboration agreement mentioned in this
release will lead to identifying a pre-clinical candidate. Nor
is there any guarantee that if one is identified, it will be
successfully developed or approved for any of the indications
described in this release. Forward-looking statements in this press
release should be evaluated together with the many uncertainties
that affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2014 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150830005034/en/
Bristol-Myers SquibbMedia:Sarah Koenig,
609-252-4145sarah.koenig@bms.comorInvestors:Ranya Dajani,
609-252-5330ranya.dajani@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.comorQIMR
BerghoferMedia:Kim Lyell,
61-7-3845-3699kim.lyell@qimrberghofer.edu.auorClaire Cameron,
61-7-3362-0291claire.cameron@qimrberghofer.edu.au
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024